Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
[Recommendations for a brief international cognitive assessment for multiple sclerosis].
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Mycophenolate mofetil therapy in the management of inflammatory bowel disease - A retrospective case series and review.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
BIIB033 single ascending dose study in healthy volunteer subjects
Seeing illness in art and medicine: a patient and printmaker collaboration.
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS
Gender as risk factor for autoimmune diseases.
Improving the translational hit of experimental treatments in multiple sclerosis.
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.
Parenteral Dilantin®
Recruiting women smokers: the engineering of consent.

Pages